Umecrine Cognition Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 8

Umecrine Cognition General Information

Description

Developer of pharmaceutical products designed to treat cognitive neurological disorders. The company focuses on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids, enabling healthcare industries to provide treatment that directly addresses the neurocognitive signs and symptoms of Hepatic encephalopathy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Corporate Office
  • Karolinska Institutet Science Park
  • Nanna Svartz väg 6A
  • 171 65 Solna
  • Sweden
+46 070-918 00 00

Umecrine Cognition Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Umecrine Cognition Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Accelerator/Incubator 000.00 Completed Clinical Trials - Phase 2
8. Later Stage VC 17-Nov-2023 00.000 000.00 Completed Clinical Trials - Phase 2
7. Debt - General 28-Mar-2023 00.000 000.00 Completed Clinical Trials - Phase 2
6. Later Stage VC 14-Sep-2022 00.000 000.00 Completed Clinical Trials - Phase 2
5. Later Stage VC 14-Jul-2021 00.00 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC 31-Dec-2019 000.00 000.00 00000 Completed Clinical Trials - Phase 2
3. Later Stage VC 04-Oct-2017 00.000 00.000 Completed Clinical Trials - Phase 2
2. Later Stage VC 22-Nov-2016 $4.96M $5.4M 00.000 Completed Clinical Trials - Phase 2
1. Early Stage VC 31-Dec-2011 $438K $438K 00.000 Completed Startup
To view Umecrine Cognition’s complete valuation and funding history, request access »

Umecrine Cognition Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference 00,000 0000.00 0000.00 00 0000.00 0.00
Preference 0,000 000.0 000.0 00 000.0 0.00
Preference 00,000 000.00 000.00 00 000.00 00.000
Preference 199,950 $16.96 $16.96 1x $16.96 39.72%
Preference 20,833 $15.27 $15.27 1x $15.27 4.14%
To view Umecrine Cognition’s complete cap table history, request access »

Umecrine Cognition Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of pharmaceutical products designed to treat cognitive neurological disorders. The company focuses on finding
Drug Discovery
Solna, Sweden
2 As of 2022
000.00
000000000000 000.00

000000

uis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu f
0000 000000000
Solna, Sweden
0 As of 0000
000.00
000000 - 000 000.00

000000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad m
0000 000000000
Solna, Sweden
00 As of 0000
00000
0000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Umecrine Cognition Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dilafor Venture Capital-Backed Solna, Sweden 0 000.00 000000 - 000 000.00
Scandinavian Biopharma Venture Capital-Backed Solna, Sweden 00 00000 0000000000 00000
AlzeCure Pharma Corporate Backed or Acquired Huddinge, Sweden 00 000.00 00000000 000.00
You’re viewing 3 of 3 competitors. Get the full list »

Umecrine Cognition Patents

Umecrine Cognition Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4389129-A1 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia Pending 22-Dec-2022 0000000000 0
CA-3237550-A1 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor Pending 10-Nov-2021 00000000000
CA-3137019-A1 New medical use Pending 29-Oct-2021 000000000
US-20230134958-A1 New medical treatment Inactive 29-Oct-2021 0000000000 0
EP-4079307-A1 New medical use Inactive 20-Apr-2021 A61K31/568 0
To view Umecrine Cognition’s complete patent history, request access »

Umecrine Cognition Executive Team (6)

Name Title Board Seat Contact Info
Hans Toll Chief Financial Officer
Magnus Doverskog Ph.D Chief Scientific Officer & Senior Vice President
Lars Öhman Senior Advisor
Anders Karlsson Chief Executive Officer & Board Member
Eva Arlander Ph.D Chief Development Officer
You’re viewing 5 of 6 executive team members. Get the full list »

Umecrine Cognition Board Members (7)

Name Representing Role Since
Anders Karlsson Self Chief Executive Officer & Board Member 000 0000
Bruce Scharschmidt Ph.D Umecrine Cognition Board Member 000 0000
John Öhd Ph.D Karolinska Development Board Member 000 0000
Thomas Blackburn Ph.D Umecrine Cognition Board Member 000 0000
Torbjörn Bäckström MD Self Founder & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Umecrine Cognition Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Umecrine Cognition Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Ribbskottet Corporation 000 0000 000000 0
AB Ility Venture Capital Minority 000 0000 000000 0
Almi Invest Venture Capital Minority 000 0000 000000 0
Fort Knox (Umea) Family Office Minority 000 0000 000000 0
Karolinska Development Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Umecrine Cognition FAQs

  • When was Umecrine Cognition founded?

    Umecrine Cognition was founded in 2006.

  • Who is the founder of Umecrine Cognition?

    Torbjörn Bäckström MD is the founder of Umecrine Cognition.

  • Who is the CEO of Umecrine Cognition?

    Anders Karlsson is the CEO of Umecrine Cognition.

  • Where is Umecrine Cognition headquartered?

    Umecrine Cognition is headquartered in Solna, Sweden.

  • What is the size of Umecrine Cognition?

    Umecrine Cognition has 2 total employees.

  • What industry is Umecrine Cognition in?

    Umecrine Cognition’s primary industry is Drug Discovery.

  • Is Umecrine Cognition a private or public company?

    Umecrine Cognition is a Private company.

  • What is Umecrine Cognition’s current revenue?

    The current revenue for Umecrine Cognition is 000000.

  • How much funding has Umecrine Cognition raised over time?

    Umecrine Cognition has raised $33.7M.

  • Who are Umecrine Cognition’s investors?

    Ribbskottet, AB Ility, Almi Invest, Fort Knox (Umea), and Karolinska Development are 5 of 8 investors who have invested in Umecrine Cognition.

  • Who are Umecrine Cognition’s competitors?

    Dilafor, Scandinavian Biopharma, and AlzeCure Pharma are competitors of Umecrine Cognition.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »